-
Press Release
test media release format
-
Press Release
test media release format
-
Story
My journey to Novartis: Finding my purpose and passion -
Press Release
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
-
Press Release
Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024
-
Press Release
Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
-
Press Release
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
-
Press Release
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
-
Story
Drug delivery, service delivery, and the future of cancer care -
Press Release
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
-
Press Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
-
Press Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire